Tag: neoadjuvant

Olaparib in BRCA+ Breast Cancer

New clinical data show that the PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) also has a place in the treatment of early stage breast cancer with BRCA...

FDA Approves Ozanimod (Zeposia) for Ulcerative Colitis

The US Food and Drug Administration (FDA) has approved ozanimod (Zeposia) for adults with moderately to severely active ulcerative colitis (UC), the company has announced....

Neoadjuvant Systemic Therapy Promising for Resectable Colorectal Peritoneal Metastases

NEW YORK (Reuters Health) – Perioperative systemic therapy seemed feasible, safe and capable of inducing a response in a phase 2 trial comparing the treatment...

Bladder Cancer Indication Withdrawn for Durvalumab

After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be withdrawn in the United States...

Better Survival With S-1/Docetaxel in Stage III Gastric Cancer

A new recommendation for the treatment of patients with gastric cancer has been proposed on the basis of final results from the phase 3 trial...

New Standard Emerges for Locally Advanced Rectal Cancer

A new approach to the treatment of patients with high-risk, locally advanced rectal cancer reduces the rate of treatment failure, and may also increase rate...

Adding Atezolizumab to Chemo Doesn’t Worsen QOL in Early TNBC

Adding the immune checkpoint inhibitor atezolizumab to first-line therapy for early triple-negative breast cancer (TNBC) did not significantly worsen patients’ quality of life, according to...

Palbociclib Disappoints in HR+, HER2– Breast Cancer

The CDK4/6 inhibitor palbociclib provides no significant benefit in patients with hormone receptor–positive (HR+), HER2-negative primary breast cancer, according to first results from the PENELOPE-B...

What’s Hot, Including a Major Chemotherapy Trial

The “hottest” presentation at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS) comes from RxPONDER (abstract GS3-00), a major randomized clinical trial assessing use...

Immediate Breast Reconstruction Feasible Following Neoadjuvant Chemo

NEW YORK (Reuters Health) – Long-term oncologic outcomes following neoadjuvant chemotherapy for breast cancer are similar with immediate breast reconstruction and conventional mastectomy alone, regardless...

pCR in HER2+ Breast Cancer Predicts Long-Term Survival

A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG...

Image-Guided Biopsy May Help Some Avoid Breast Cancer Surgery

NEW YORK (Reuters Health) – Following neoadjuvant chemotherapy, image-guided vacuum-assisted biopsy (VAB) can reliably identify a subgroup of patients with no residual disease in the...

Oncologists Train ARDS Docs for ‘Inspirational’ COVID-19 Trial

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Oncologists in the long-running I-SPY 2 platform trial are training physicians...

Ophthalmologists Called to Catch Cancers Earlier

Significant advances in the management of eye cancer mean that early referrals to subspecialists are crucial when ophthalmologists suspect disease in their patients, two leaders...

CRC With Peritoneal Metastases: CRS-HIPEC Refinements

Patients with colorectal cancer (CRC) who have peritoneal metastases should only be treated in a specialized referral center and given systemic chemotherapy before cytoreductive surgery...

Nivolumab for Tough Tumor, End-of-Life Wording

Here are the most important stories that Medscape Oncology’s editors picked for you to read today: Nivolumab for a Rare, Aggressive Tumor Neoadjuvant nivolumab (Opdivo, Bristol-Myers...

Transplant Beats Bortezomib-Based Therapy for MM

While upfront autologous transplantation has bested bortezomib-based intensification therapy in a large, randomized multiple myeloma (MM) trial, investigators and observers say more research will be...

Neoadjuvant Nivolumab ‘Promising’ in Merkel Cell Carcinoma

Neoadjuvant nivolumab (Opdivo, Bristol-Myers Squibb) could improve outcomes for patients with high-risk resectable Merkel cell carcinoma (MCC), say researchers reporting the first trial in this...

EHA Webinar Addresses Treating AML Patients With COVID-19

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. A hematologist in Italy shared his personal experience addressing the intersection...

Survival & NAC Use Continue to Increase

Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median...